PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Richard S. Finn, MD - The Expanding Playbook of Hepatocellular Carcinoma: Examining Scientific Data and Evidence With Your Multidisciplinary Team
Go online to PeerView.com/UHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hepatocellular carcinoma (HCC) discuss how to effectively care for patients with HCC using multidisciplinary strategies in the context of an expanded and novel treatment arsenal. The faculty discusses pivotal clinical evidence of approved targeted and immune checkpoint inhibitor agents and how to effectively select and integrate therapies into individualized treatment plans for patients with HCC. Upon completion of this activity, participants will be able to: Appraise pivotal safety and efficacy data on approved targeted and immune checkpoint therapies for advanced HCC, Describe the significance of emerging data that continue to evolve the standards of care for patients with HCC, including biomarker-driven therapies, combination strategies using immunotherapy and targeted therapies, and novel therapeutic approaches for locoregional disease, Manage anticipated adverse events associated with targeted therapy and immunotherapy for patients with advanced HCC, Select optimal therapeutic options, including consideration of clinical trials, in the first and second lines of treatment for patients with advanced HCC, Incorporate multidisciplinary care approaches for the management of challenging patients with HCC, including those with locoregional disease who are candidates for early transition to systemic therapy or those with Child–Pugh B status, among others